Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1088-1092. doi: 10.19723/j.issn.1671-167X.2020.06.016
Previous Articles Next Articles
Yi-ming ZHENG,Hong-jun HAO,Yi-lin LIU,Jing GUO,Ya-wen ZHAO,Wei ZHANG,Yun YUAN()
CLC Number:
[1] |
Cruellas MG, Viana VS, Levy-Neto M, et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis[J]. Clinics (Sao Paulo), 2013,68(7):909-914.
doi: 10.6061/clinics |
[2] |
Lee A. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J]. Rheumatol Int, 2017,37(8):1323-1333.
doi: 10.1007/s00296-017-3718-1 pmid: 28417151 |
[3] |
Rutjes SA, Vree EW, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy[J]. Clin Exp Immunol, 1997,109(1):32-40.
doi: 10.1046/j.1365-2249.1997.4081308.x pmid: 9218821 |
[4] |
Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical review[J]. J Autoimmun, 2012,39(1/2):77-82.
doi: 10.1016/j.jaut.2012.01.014 |
[5] |
Damoiseaux J, Boesten K, Giesen J, et al. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens[J]. Ann N Y Acad Sci, 2005,1050:340-347.
doi: 10.1196/annals.1313.036 pmid: 16014550 |
[6] |
Frank MB, Mccubbin V, Trieu E, et al. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies[J]. J Autoimmun, 1999,12(2):137-142.
doi: 10.1006/jaut.1998.0265 pmid: 10047434 |
[7] |
Brouwer R, Hengstman GJ, Vree EW, et al. Autoantibody profiles in the sera of European patients with myositis[J]. Ann Rheum Dis, 2001,60(2):116-123.
doi: 10.1136/ard.60.2.116 pmid: 11156543 |
[8] |
Venables PJ. Antibodies to Jo-1 and Ro-52: why do they go together?[J]. Clin Exp Immunol, 1997,109(3):403-405.
doi: 10.1046/j.1365-2249.1997.4761369.x pmid: 9328112 |
[9] |
Bundell C, Rojana-Udomsart A, Mastaglia F, et al. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing[J]. Pathology, 2016,48(4):363-366.
doi: 10.1016/j.pathol.2016.03.012 pmid: 27114370 |
[10] |
Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J]. Semin Arthritis Rheum, 2012,41(6):890-899.
doi: 10.1016/j.semarthrit.2011.09.008 pmid: 22078416 |
[11] | 孟令超, 李毅, 张巍, 等. Jo-1综合征的临床及骨骼肌病理特点[J]. 中华医学杂志, 2016,96(29):2352-2355. |
[12] |
Yamasaki Y, Satoh M, Mizushima M, et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52[J]. Mod Rheumatol, 2016,26(3):403-409.
doi: 10.3109/14397595.2015.1091155 pmid: 26344678 |
[13] |
Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response[J]. J Rheumatol, 2016,43(8):1566-1574.
doi: 10.3899/jrheum.150844 pmid: 27252419 |
[14] |
Ben-Chetrit E, Chan EK, Sullivan KF, et al. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle[J]. J Exp Med, 1988,167(5):1560-1571.
doi: 10.1084/jem.167.5.1560 pmid: 3367095 |
[15] |
Peene I, Meheus L, de Keyser S, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease[J]. Ann Rheum Dis, 2002,61(10):929-933.
doi: 10.1136/ard.61.10.929 pmid: 12228166 |
[16] |
Menendez A, Gomez J, Escanlar E, et al. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection[J]. Autoimmunity, 2013,46(1):32-39.
pmid: 23039326 |
[17] |
Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J]. Rheumatol Int, 2016,36(7):935-943.
doi: 10.1007/s00296-016-3494-3 pmid: 27193471 |
[18] |
Gunnarsson R, El-Hage F, Aalokken TM, et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease[J]. Rheumatology (Oxford), 2016,55(1):103-108.
doi: 10.1093/rheumatology/kev300 |
[1] | Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734. |
[2] | Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292. |
[3] | Yan-hong MENG,Yi-fan CHEN,Pei-ru ZHOU. Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1088-1096. |
[4] | Lu ZHANG,Cheng CHEN,Mei-ting WENG,Ai-ping ZHENG,Mei-ling SU,Qing-wen WANG,Yue-ming CAI. Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1094-1098. |
[5] | Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218. |
[6] | Yi-cen YING,Qi TANG,Kai-wei YANG,Yue MI,Yu FAN,Wei YU,Yi SONG,Zhi-song HE,Li-qun ZHOU,Xue-song LI. Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 644-651. |
[7] | ZHANG Pu-li,YANG Hong-xia,ZHANG Li-ning,GE Yong-peng,PENG Qing-lin,WANG Guo-chun,LU Xin. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1055-1060. |
[8] | LUO Lan,XING Xiao-yan,XIAO Yun-shu,CHEN Ke-yan,ZHU Feng-yun-zhi,ZHANG Xue-wu,LI Yu-hui. Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1078-1082. |
[9] | XIAO Yun-shu,ZHU Feng-yun-zhi,LUO Lan,XING Xiao-yan,LI Yu-hui,ZHANG Xue-wu,SHEN Dan-hua. Clinical and immunological characteristics of 88 cases of overlap myositis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1088-1093. |
[10] | YI Wen-xia,WEI Cui-jie,WU Ye,BAO Xin-hua,XIONG Hui,CHANG Xing-zhi. Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1191-1195. |
[11] | Feng-yun-zhi ZHU,Xiao-yan XING,Xiao-fei TANG,Yi-min LI,Miao SHAO,Xue-Wu ZHANG,Yu-hui LI,Xiao-lin SUN,Jing HE. Clinical and immunological characteristics of myositis complicated with thromboembolism [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 995-1000. |
[12] | Jing ZHAO,Feng SUN,Yun LI,Xiao-zhen ZHAO,Dan XU,Ying-ni LI,Yu-hui LI,Xiao-lin SUN. Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1009-1013. |
[13] | Yu-zhou GAN,Yu-hui LI,Li-hua ZHANG,Lin MA,Wen-wen HE,Yue-bo JIN,Yuan AN,Zhan-guo LI,Hua YE. Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1001-1008. |
[14] | Jiao-niu DUAN,Wei DU,Rui-hong HOU,Ke XU,Gai-lian ZHANG,Li-yun ZHANG. Progressive necrosis of lipid: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1182-1184. |
[15] | Jing XU,Jing XU,He LI,Jie TANG,Jian-long SHU,Jing ZHANG,Lian-jie SHI,Sheng-guang LI. Dermatomyositis combined with IgA vasculitis: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1173-1177. |
|